Free Trial
→ My public warning after 55 years of watching the markets (From Weiss Ratings) (Ad)tc pixel
OTCMKTS:DSRLF

DiaSorin Earnings Date & Estimates

DiaSorin logo
$92.00 0.00 (0.00%)
As of 10/30/2026

DiaSorin is estimated to report earnings on Thursday, November 5, 2026.

Research:ProfileForecast

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from DiaSorin

DiaSorin is expected to post earnings of $2.46 per share on revenue of $340.73 million.

Consensus Estimates

Consensus EPS
$2.46
Expected Revenue
$340.73 million

Prepare for the Earnings Call

DiaSorin Earnings FAQ

DiaSorin (OTCMKTS:DSRLF) is estimated to report earnings on Thursday, November 5, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect DiaSorin to post earnings of $2.46 per share for the quarter.

The consensus revenue estimate for DiaSorin is $340.73 million for the quarter.

DiaSorin Earnings Headlines

DiaSorin (DSRLF) Set to Post Quarterly Earnings on Thursday
October 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31165617
DiaSorin S.p.A. (DSRLF) Q2 2026 Earnings Call Transcript
August 1, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4928960-diasorin-s-p-a-dsrlf-q2-2026-earnings-call-transcript
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
November 3 at 1:00 AM  |  Porter & Company (Ad)
DiaSorin speculated to have rebuffed takeover offer from US suitor - report
July 11, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/diasorin-speculated-to-have-rebuffed-takeover-offer-from-us-suitor-report/ar-AA27ES1G
DiaSorin S.p.A. (DSRLF) Q1 2026 Earnings Call Transcript
May 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4901628-diasorin-s-p-a-dsrlf-q1-2026-earnings-call-transcript
Diasorin S.p.A. (DSRLF)
April 19, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/dsrlf
See More DiaSorin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DiaSorin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DiaSorin and other key companies, straight to your email.

About DiaSorin

DiaSorin (OTCMKTS:DSRLF) is an Italian company specializing in in vitro diagnostics, with a focus on immunodiagnostics and molecular diagnostics. Its products are used by hospitals, clinical laboratories and healthcare providers to support the detection, diagnosis and monitoring of a range of diseases and medical conditions.

The company’s portfolio includes automated immunoassay systems, reagents and diagnostic tests marketed under the LIAISON family, as well as molecular diagnostic platforms and assays. Its testing solutions address areas such as infectious diseases, endocrinology, oncology, gastrointestinal conditions and other specialty diagnostic needs.

Headquartered in Saluggia, Italy, DiaSorin serves customers internationally through operations and commercial activities across Europe, North America, Asia and other global markets. The company developed from Italy’s in vitro diagnostics industry and has expanded its presence through product development and acquisitions, including its molecular diagnostics business. Carlo Rosa serves as DiaSorin’s chief executive officer.

View DiaSorin Profile
Earnings Tools